10x Genomics, Inc. (NASDAQ:TXG) Insider Sells $98,028.03 in Stock

10x Genomics, Inc. (NASDAQ:TXG) insider Benjamin J. Hindson sold 4,351 shares of the firm’s stock in a transaction dated Thursday, August 22nd. The stock was sold at an average price of $22.53, for a total transaction of $98,028.03. Following the completion of the transaction, the insider now owns 345,704 shares in the company, valued at $7,788,711.12. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

10x Genomics Stock Down 1.2 %

Shares of TXG opened at $22.29 on Thursday. The firm’s 50 day moving average is $19.75 and its 200-day moving average is $28.10. 10x Genomics, Inc. has a 12-month low of $15.28 and a 12-month high of $57.90.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. UBS Group cut their price objective on shares of 10x Genomics from $30.00 to $25.00 and set a “neutral” rating on the stock in a research report on Tuesday, August 13th. Deutsche Bank Aktiengesellschaft downgraded shares of 10x Genomics from a “buy” rating to a “hold” rating and cut their price objective for the company from $55.00 to $25.00 in a research report on Wednesday, July 10th. JPMorgan Chase & Co. downgraded shares of 10x Genomics from an “overweight” rating to a “neutral” rating and cut their price objective for the company from $40.00 to $20.00 in a research report on Thursday, July 18th. Canaccord Genuity Group lowered their target price on shares of 10x Genomics from $50.00 to $32.00 and set a “buy” rating on the stock in a research note on Tuesday, July 23rd. Finally, Stifel Nicolaus lowered their target price on shares of 10x Genomics from $53.00 to $25.00 and set a “buy” rating on the stock in a research note on Tuesday, July 16th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, 10x Genomics has a consensus rating of “Hold” and a consensus target price of $31.46.

Hedge Funds Weigh In On 10x Genomics

Several hedge funds have recently made changes to their positions in TXG. Allspring Global Investments Holdings LLC grew its stake in shares of 10x Genomics by 113.5% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 698 shares of the company’s stock worth $26,000 after purchasing an additional 371 shares during the last quarter. First Horizon Advisors Inc. increased its position in shares of 10x Genomics by 74.1% in the second quarter. First Horizon Advisors Inc. now owns 1,898 shares of the company’s stock worth $37,000 after acquiring an additional 808 shares in the last quarter. Covestor Ltd increased its position in shares of 10x Genomics by 501.7% in the first quarter. Covestor Ltd now owns 1,047 shares of the company’s stock worth $39,000 after acquiring an additional 873 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of 10x Genomics in the first quarter worth approximately $71,000. Finally, Van ECK Associates Corp increased its position in shares of 10x Genomics by 23.4% in the fourth quarter. Van ECK Associates Corp now owns 1,908 shares of the company’s stock worth $107,000 after acquiring an additional 362 shares in the last quarter. Institutional investors and hedge funds own 84.68% of the company’s stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.